New York, NY -- (SBWIRE) -- 12/04/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Progenics Pharmaceuticals, Inc (NASDAQ:PGNX), Orexigen Therapeutics, Inc (NASDAQ:OREX), The Dow Chemical Company (NYSE:DOW), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) showed a volume of 1.39million shares by the end of last trade whereas the average volume of the stock remained 527,776.00 shares. The stock opened the session at $4.82 but then moved to $4.82. At that price, the stock showed a negative performance of -1.04%. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC,
Will PGNX Get Buyers Even After The Recent Rally? Find Out Here
Orexigen Therapeutics, Inc (NASDAQ:OREX) opened the session at $6.26 and closed the session at $6.12. The stock showed a negative performance of -0.97% in previous trading session. Traded with volume of 9.60 million shares in the prior session and the average volume of the stock remained 2.01 million shares. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Has OREX Found The Bottom And Ready To Gain Momentum? Find Out Here
The Dow Chemical Company (NYSE:DOW) opened the session at $39.81 and closed the session at $38.72. The stock showed a negative performance of -3.15% in previous trading session. Traded with volume of 10.89 million shares in the prior session and the average volume of the stock remained 6.91 million shares. The beta of the stock remained 2.68. The Dow Chemical Company combines the power of science and technology to passionately innovate what is essential to human progress. The Company connects chemistry and innovation with the principles of sustainability to help address many of the problems, such as the need for clean water, renewable energy generation and conservation, and increasing agricultural productivity.
Why Should Investors Buy DOW After the Recent Fall? Just Go Here and Find Out
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) the stock decreased -1.65% and finished the session at $68.60. Traded with volume of 543,612.00 shares in the prior session and the average volume of the stock remained 348,337.00 shares. The beta of the stock remained 0.83. Roche Holding AG is a Swiss pharmaceuticals and diagnostics holding company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring.
Will RHHBY Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)